Elixir Associates’ Post

Elixir Associates reposted this

View profile for Nahum Wood, graphic

Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe

Big news as Obsidian Therapeutics has just received FDA Fast Track Designation for OBX-115, a groundbreaking T-cell therapy aimed at treating metastatic or locally advanced melanoma that resists PD-1/PD-L1 inhibitors. This means the development and review process for OBX-115 will speed up, providing much-needed hope for patients who have exhausted other treatment options 🚀 OBX-115 is truly innovative, harnessing patient-derived tumor-infiltrating lymphocytes (TILs) enhanced with membrane-bound interleukin-15 (mbIL15). This cellular magic improves the persistence and antitumor activity of TIL therapy, potentially transforming the outcomes for melanoma patients. Clinical trials are underway, offering a glimpse into a future with more effective treatments for both melanoma and non-small cell lung cancer (NSCLC) 📊✅ With this designation, Obsidian is set for frequent interactions with the FDA and might even be eligible for Priority and Rolling Review once specific criteria are met. Exciting times ahead for the biotech field! 🎉 #ObsidianTherapeutics #Melanoma #Biotechnology #FDAApproval #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner

Obsidian’s OBX-115 T-Cell Therapy For Melanoma Receives FDA Fast Track

Obsidian’s OBX-115 T-Cell Therapy For Melanoma Receives FDA Fast Track

To view or add a comment, sign in

Explore topics